Mission
To discover and develop therapeutic solutions for unmet medical needs. Primarily focusing on the development of novel bispecific antibody constructs to better treat a wide spectrum of medical conditions ranging from cancer to autoimmune disease.
Product
Indication
In Vitro Confirmation of Lead Candidate
Efficacy Study in Animal Model
Candidate Confirmation
Pre-clinical Study
Clinical
Bispecific Antibody
BAB-05
TCI-312
AF-29
lCM-053
Antibody Conjugates
TCI=212
BTA-024
Recombinant Proteins
Proprietary Technology Platform
BsAbs (bispecific antibodies) can recognize two epitopes on the same target or two different targets concurrently to provide improved efficacy via multiple molecular mechanisms or synergistic effects. However, the design principles require a high level of immunological understanding to modulating affinity ratio between targets/epitopes, and the challenges in CMC, including mis-pairing in dimerization of light and heavy chain, low yield and lack of stability, as well as narrow therapeutic index have resulted in fewer bsAbs than mAbs in the market.
YiChenBio has developed four innovative (and proprietary) technology platforms of bsAbs: Monovalent Bi-Targeting Antibody (MoBiT), Tumor-relevant Immune Effector cell Modulator (TrIEM) and Directed Immune Modulatory Antibody (DIMA), which solve the key issues of current bsAbs in manufacturability and therapeutic profiles. Based on MoBiT, YiChenBio has developed a novel Multi-Functional Antibody Drug Conjugation (MF-ADC) platform with high stability and highly homogeneous drug-to-antibody ratio (DAR) .
In addition, YiChenBio has the long-acting therapeutic protein platform aiming to develop recombinant proteins which have pharmacological properties and CMC process similar to mAbs.
Bispecific Antibody Platform
MoBiT is a proprietary monovalent bispecific antibody platform for TAA-directed CD3 T cell engager, which overcomes the key issues of current BiTEs including difficulties in CMC and narrow therapeutic window. The advantages of MoBiT include:
- No heavy/light chain mis-pairing issues without, but not using scFv, VHH
- Similar manufacturability and pharmacological properties to mAb
- Easily adapt to various therapeutic target/epitope pairs
- Capable of engaging effector and target cells in close proximity to promote immunological synapse
- Flexible to modulate target affinities to balance potency and safety
- Smaller molecular size than mAb, improving tissue penetration while retaining similar half life to mAb
TrIEM is an innovative cytokine-antibody fusion platform adaptable to diverse cytokine and tumor-associated target combinations. TrIEM is expected to overcome the current barrier of immuno-cytokine in balancing long half-life and toxicity. TrIEM could significantly improve the therapeutic window while obtaining a prolonged PK profile. The advantages of TrIEM are as follows:
- No heavy/light chain mis-pairing issues; Similar manufacturability and properties to mAb
- Selectively promotes proliferation andactivation of NK cells and CD8+ T cells within tumor micro-environment (TME), while minimizing systemic IL-15 exposure and activities
- Enhanced therapeutic indexby optimized tumor targeting and controlled immuno-cytokine activities
- Extendedhalf-life and reduced target medicated clearance
- Comparable manufacturability and properties to mAb
- Potential forfurther improved therapeutic index when used in combination with immune checkpoint inhibitors
DIMA is a first-in-class cell-directed immunosuppressant bivalent bispecific antibody platform for inhibition of inflammatory signaling (IL-x) pathways with the following distinguished advantages
- First-in-class immunosuppressantbispecific antibody blocking IL-x signaling on inflammation relevant cells
- Comparablemanufacturability and pharmacological properties to mAb
- Enhanced efficacy and reducing systemic exposure
- Optimized,differentiated half-lives for the two binding domai to balance efficacy and side effects
- Superior efficacyto approved IL-x neutralizing drugs
- Applicable to a broad range of inflammatory diseases and oncology indications
MF-ADC platform
Bispecific antibody-drug conjugates represent a fast-growing class of next generation ADCs due to their potential in enhancing specificity and internalization, improving efficacy, and overcoming drug resistance. However, compared to mAbs, the current bsAb formats are not optimal as a carrier to develop bispecific antibody conjugates for challenges such as the complicated CMC process, low stability for conjugation and difficulties in controlling DAR.
MF-ADC, a proprietary platform based on proprietary MoBiT, is a novel multi-functional antibody-drug conjugation platform to overcome the current challenges of antibody conjugates in manufacture and efficacy. Advantages of YiChen’s MF-ADC platform includes:
- Based on innovative monovalent bispecific antibody platform (MoBiT)
- Fullycompatible with clinically validated conjugation chemistries and linker/payload technologies
- High stability of conjugated proteinswith minimal degradation or aggregation
- Highly homogeneous DAR forconjugated products
- Combination of high specificity and efficientinternalization ensures precise and specific tumor cell killing
- Amenable to incorporate of additional functional modules
Long-acting protein
Peptides and proteins account for a significant type of therapeutic modality due to their important roles in many different disease pathologies. However, the clinical potential of these biomolecules is often hampered by their inherent short serum half-life. A number of long-acting technologies can extend the half-life of protein and peptide therapeutics and significantly improve patient compliance, while also optimizing the physicochemical properties and enhancing their safety and efficacy.
- Innovative design of therapeutic protein with prolonged half-lives
- Similar manufacturability and pharmacological properties to mAb
- Low immunogenicity